{
  "nctId": "NCT02418949",
  "briefTitle": "Altering Activation Patterns Post-stroke",
  "officialTitle": "Altering Activation Patterns in the Distal Upper Extremity After Stroke",
  "protocolDocument": {
    "nctId": "NCT02418949",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2020-06-23",
    "uploadDate": "2021-04-09T14:49",
    "size": 2876056,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02418949/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 96,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-11",
    "completionDate": "2023-12",
    "primaryCompletionDate": "2019-08",
    "firstSubmitDate": "2015-02-05",
    "firstPostDate": "2015-04-17"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Chronic, severe hand hemiparesis resulting from a single stroke (Chedoke- McMaster Stroke Assessment: Stage of Hand 2 or 3)\n* Single stroke occurring at least 6 months prior to enrollment\n* Spasticity\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Excessive pain in paretic upper limb\n* Hemispatial neglect (as assessed by the Behavioral Inattention Test)\n* Apraxia (as assessed by the FABERS battery)\n* Botulinum toxin injection in the upper extremity within the past 6 months\n* Introduction of new anti-spasticity medication within the past 6 months\n* Orthopaedic impairments\n* History of seizure disorder\n* Other major health impairment",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT)",
        "description": "GWMFT is a clinical outcome measure comprised of 15 timed tasks focusing on upper extremity function. Maximum allowable time per task is 120 seconds.",
        "timeFrame": "baseline and 9 weeks (immediately post intervention)"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC)",
        "description": "Following a maximum voluntary contraction (MVC) -- Time (s) required for muscle electromyographic (EMG) signals to reduce to within 3 SD of pre-MVC EMG activity.",
        "timeFrame": "baseline and 9 weeks (immediately post intervention)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:36.514Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}